|Download document||Second draft public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs)|
|Reference number||EMA/HMPC/893108/2011 2nd draft|
|Status||draft: consultation open|
|Consultation start date||14/11/2013|
|Consultation end date||15/02/2014|
|Email address for firstname.lastname@example.org|
It became apparent during assessment of Symphytum officinale (monograph EMEA/HMPC/572844/2009) that the risk assessment of pyrrolizidine alkaloids (PAs) poses considerable difficulties, with several PAs being regarded as both hepatotoxic and carcinogenic. Considering that PAs are natural constituents of a number of plants used for medicinal purposes and that PAs might be part of the food chain, the HMPC decided to prepare a public statement on the use of herbal preparations containing PAs.